Dr. Peter Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine, joins Ali Velshi to discuss the “pause” on the Johnson & Johnson vaccine in the United States after the discovery of 6 rare cases of blood clotting in women who were immunized with the shot. The goal, says Hotez, is to identify a specific group who might be at higher risk, and that requires a little time. “Even though the U.S. Has other options, many countries don’t. For many countries, all they have are the J & J, AstraZeneca vaccine and the Russian Sputnik V vaccine,” all of which are non-mNRA and have the potential to behave similarly. Says Hotez, “It is critical to sort this out not only to protect American citizens, but to protect the world.”
Comments are closed.